Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

被引:2
|
作者
Hariri, Nosaibah [1 ]
Hasteh, Farnaz [1 ]
Walavalkar, Vighnesh [1 ]
Roma, Andres A. [1 ]
Fadare, Oluwole [1 ]
机构
[1] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
关键词
repeat testing; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; CORE-NEEDLE; CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; AMERICAN SOCIETY; HER2; DISCORDANCE; ER; RECOMMENDATIONS;
D O I
10.1097/PAI.0000000000000525
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2.5-year period and analyzed the subset (n=153) for which testing was performed on the excision specimen solely due to the fact that testing on the preceding biopsy was performed at an outside institution. The rates and directions of biopsy-to-excision change were as follows: ER [1.3% (2/153), 100% from (+) to (-)]; PR [4% (6/153), 83% from (+) to (-)]; HER2/neu assessed by immunohistochemistry [21% (29/137)]; HER2/neu assessed by fluorescence in situ hybridization [3.3% (2/61); 50% from amplified to nonamplified and 50% vice versa]. There were no ER(-) and PR(-) biopsy cases that became ER and/or PR(+) in the excision. By coordinate analysis for the hormone receptors [ie, ER and/or PR(+) being indicative of "hormone receptor" (HR) positivity], there were no cases that changed from HR(+) in the biopsy to HR(-) in the excision (or vice versa), which suggests that repeat testing for ER and PR in this setting is of limited value. In an analysis that incorporated both immunohistochemistry and in situ fluorescence hybridization results, there were 2 cases with a clinically significant biopsy-to-excision change in HER2/neu status in which that change was detected primarily because the excision was retested. These findings provide baseline data for formulating policies on whether repeat testing should routinely be performed in the described scenario.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [21] Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer
    Qin Qinghong
    Gao Fangfang
    Jiang Wei
    Tan Qixing
    Mo Qinguo
    Wei Changyuan
    中华医学杂志(英文版), 2014, (18) : 3272 - 3277
  • [22] Immunoexpression of claudin-4 and correlation with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-neu in breast cancer
    Kumar, Niranjan
    Tandon, Megha
    Chintamani, C. M.
    Saxena, Sunita
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (06) : 1766 - 1770
  • [23] Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients
    Zhao, Xingjuan
    Yang, Xuan
    Fu, Lei
    Yu, Keda
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4579 - 4586
  • [24] Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
    Walter, Vincent
    Fischer, Chiara
    Deutsch, Thomas M.
    Ersing, Catherine
    Nees, Juliane
    Schuetz, Florian
    Fremd, Carlo
    Grischke, Eva-Maria
    Sinn, Peter
    Brucker, Sara Y.
    Schneeweiss, Andreas
    Hartkopf, Andreas D.
    Wallwiener, Markus
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 137 - 144
  • [25] Human epidermal growth factor receptor 2 testing recommendation
    Raji, Adekunle
    Lurie, Robert H.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (09) : 1330 - 1331
  • [26] Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
    Vincent Walter
    Chiara Fischer
    Thomas M. Deutsch
    Catherine Ersing
    Juliane Nees
    Florian Schütz
    Carlo Fremd
    Eva-Maria Grischke
    Peter Sinn
    Sara Y. Brucker
    Andreas Schneeweiss
    Andreas D. Hartkopf
    Markus Wallwiener
    Breast Cancer Research and Treatment, 2020, 183 : 137 - 144
  • [27] Human epidermal growth factor receptor 2 testing recommendation
    Raji, Adekunle
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 4020 - 4021
  • [28] Correlation between microRNA-21, microRNA-206 and estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 in breast cancer
    Chen, Yuanwen
    Wu, Nian
    Liu, Lei
    Dong, Huaying
    Wu, Chengyi
    CLINICAL BIOCHEMISTRY, 2019, 71 : 52 - 57
  • [29] Methylated p16 gene is associated with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer
    Zhang, Shun-Li
    Wang, Ya-Qi
    Zhang, Jing-Hua
    Hu, Ji-Wei
    Ma, Jie
    Gu, Zheng
    Wang, Yu
    Chen, Jing-Jing
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (03) : 530 - 536
  • [30] Characterization of Estrogen Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Li, Ming
    Lv, Hong
    Shui, Ruohong
    Lu, Hongfen
    Yang, Wentao
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 151 - 151